Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome

Yamauchi, Takahiro; Ishida, Kentaro; Iwashima, Yoshiko; Ikegaya, Satoshi; Kawai, Yasukazu; Wakahara, Mami; Kumakiri, Masanobu; Ueda, Takanori

doi:10.1007/s10156-003-0254-6

Cited by 16 publications

(7 citation statements)

References 10 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar situation is also present for pyoderma gangrenosum, a paraneoplastic process seen often with IBD, including ulcerative colitis or Crohn's disease and MDS [37,38]. Therefore, it can be considered as an autoinflammatory process associated with hematopoietic malignancies.…”

Section: Discussionmentioning

confidence: 97%

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution

Peker¹,

Padron²,

Bennett

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

Chronic myelomonocytic leukemia (CMML), a clonal hematopoietic stem cell disease, may be linked to immune-mediated processes and/or autoimmune disorders (AID), although the exact pathogens are still elusive. We retrospectively analyzed 123 CMML patients in our institution. Twenty-four CMML patients (19.5%) had at least one immune-mediated disorder, most commonly idiopathic thrombocytopenic purpura, gout and psoriasis. Four of these 24 patients (15%) had more than one AID. We found that, in contrast to the general population with a prevalence rate of 3.2-5.2%, newly diagnosed CMML patients demonstrated a high prevalence and variety of immune-mediated processes and/or AID. When we compared the results with those of myelodysplastic syndromes published in the literature, the prevalence of AID in these two groups of patients is similar. Our results also showed that the presence of cytogenetic abnormalities was less in CMML patients with AID (6 of 21; 28.6%) than in those without AID (37 of 94; 39.4%), although there was no statistical significance (p = 0.334). A multicenter large cohort study of CMML with AID is recommended to illustrate the molecular relationship between the two distinct groups. © 2014 S. Karger AG, Basel

show abstract

Section: Discussionmentioning

confidence: 97%

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution

Peker¹,

Padron²,

Bennett

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Randomized controlled trials utilizing systemic agents for PG are lacking. In patients with particularly aggressive or painful disease, intravenous pulse corticosteroids (1 g methylprednisolone/day for 1-5 days) can also be used initially while awaiting the onset of a steroidsparing agent (85)(86)(87). The starting dose of oral prednisone ranges from 0.5 to 2 mg/kg/day and should be tapered over 4-6 weeks while starting a steroid-sparing agent.…”

Section: First-line Therapymentioning

confidence: 99%

“…In another series of 44 patients, most patients required long-term therapy to avoid recurrence, emphasizing the need for a steroid-sparing agent (47). In patients with particularly aggressive or painful disease, intravenous pulse corticosteroids (1 g methylprednisolone/day for 1-5 days) can also be used initially while awaiting the onset of a steroidsparing agent (85)(86)(87).…”

Section: First-line Therapymentioning

confidence: 99%

Management of neutrophilic dermatoses

Schadt

Callen

2012

Dermatol Ther

View full text Add to dashboard Cite

Neutrophilic dermatoses, including Sweet's syndrome, pyoderma gangrenosum, and rheumatoid neutrophilic dermatitis, are inflammatory conditions of the skin often associated with underlying systemic disease. These are characterized by the accumulation of neutrophils in the skin. The associated conditions, potential for systemic neutrophilic infiltration, and therapeutic management of these disorders can be similar. Sweet's syndrome can often be effectively treated with a brief course of systemic corticosteroids. Pyoderma gangrenosum, however, can be recurrent, and early initiation of a steroid-sparing agent is prudent. Second-line treatment for both of these conditions includes medications affecting neutrophil function, in addition to immunosuppressant medications.

show abstract

“…There have been 31 cases reported in the past 20 years in Japan where patients with MDS have developed PG (12). In one case, the PG was treated initially with 1g methylprednisolone daily for 3 days, with subsequent 30 mg prednisolone daily (12). The patient in our case was treated with prednisone until clearance of his lesions.…”

Section: Discussionmentioning

confidence: 99%

Neutrophilic Dermatosis of the Dorsal Hand

Bilu

Kouba

Mamelak

et al. 2004

The Journal of Dermatology

View full text Add to dashboard Cite

Neutrophilic dermatosis of the dorsal hands (NDDH) was originally described as pustular vasculitis (PV) of the hands. Recent debate focuses on categorizing this disorder in the family of neutrophilic dermatoses (ND), as opposed to a primary vasculitis. We present a case of NDDH with clinical and histologic features consistent with ND, and discuss the major concerns for this disease's reclassification.

show abstract

Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome

Cited by 16 publications

References 10 publications

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution

A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders with Chronic Myelomonocytic Leukemia: Observation from a Single Institution

Management of neutrophilic dermatoses

Neutrophilic Dermatosis of the Dorsal Hand

Contact Info

Product

Resources

About